Dechert LLP is representing Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, in its initial public offering. Forward Pharma announced today the pricing of 10,500,000 American Depositary Shares ("ADSs"), representing the Company's ordinary shares, at a price to the public of $21.00 per ADS. The ADSs are expected to begin trading today on the NASDAQ Global Select Market under the ticker symbol "FWP". The Company has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 ADSs to cover over-allotments, if any. Dechert LLP is representing Forward Pharma in this matter.

Dechert’s cross-border team representing Forward Pharma is led by corporate partners Kristopher Brown and Wayne Rapozo and includes partners Jonathan Schur (corporate) and Samuel Abrams (IP), and corporate associates Michael J. Rosenberg and Youjin Choi. Nielsen Norager Law Firm LLP in Copenhagen, Denmark, served as co-lead counsel for Forward Pharma with partner Jakob Mosegaard Larsen serving as the lead and partner Thomas Weisbjerg assisting.

Leerink Partners LLC, Jefferies LLC and RBC Capital Markets, LLC are acting as joint book-running managers. JMP Securities LLC is acting as co-manager.The underwriters were represented by K&L Gates LLP, including partners David Allen and David Lee, and associates Matthew Susson and Barry Spatzer. The underwriters used as their Danish local co-counsel the Plesner law firm, also based in Copenhagen, led by partner Thomas Holst Laursen, and attorney-at-law Henrik Laursen.